Literature DB >> 10608626

Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997.

E L Kaplan1, D R Johnson, M C Del Rosario, D L Horn.   

Abstract

BACKGROUND: Because of continuing reports from many countries of increasing resistance of group A streptococci to macrolide antibiotics, we determined the antibiotic susceptibility of recent group A streptococcal isolates from the United States.
METHODS: We evaluated 301 Streptococcus pyogenes isolates (245 from patients with uncomplicated pharyngitis and 56 isolates from patients with invasive systemic infections) for susceptibility using the Etest technique. The isolates came from 24 states and the District of Columbia during the years 1994 through 1997. Thirteen antibiotics (azithromycin, ceftriaxone, cephalothin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, imipenem, levofloxacin, oxacillin, penicillin G, tetracycline and trimethoprim-sulfamethoxazole) were studied.
RESULTS: The MIC90 for penicillin was 0.016 microg/ml, which is not significantly different from previous reports. Of the 301 isolates only 2.6% were resistant to a macrolide antibiotic and only 4% were resistant to tetracycline.
CONCLUSIONS: These data indicate that antibiotic resistance among recent isolates of group A streptococci (including those from patients with severe infections) currently is not a clinically significant problem in the United States.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608626     DOI: 10.1097/00006454-199912000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  32 in total

1.  Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile.

Authors:  E L Palavecino; I Riedel; X Berrios; S Bajaksouzian; D Johnson; E Kaplan; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong Kong.

Authors:  P L Ho; D R Johnson; A W Y Yue; D N C Tsang; T L Que; B Beall; E L Kaplan
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Azithromycin versus Penicillin in Acute Group A Streptococcal Tonsillopharyngitis.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2003-06       Impact factor: 3.725

5.  Association between resistance to erythromycin and the presence of the fibronectin binding protein F1 gene, prtF1, in Streptococcus pyogenes isolates from German pediatric patients.

Authors:  Maria Haller; Kirsten Fluegge; Sandra Jasminder Arri; Brit Adams; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Antistreptococcal activity of AR-709 compared to that of other agents.

Authors:  Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

7.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

8.  Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors:  K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Detection of multiple macrolide- and lincosamide-resistant strains of Streptococcus pyogenes from patients in the Boston area.

Authors:  Meredith E Hasenbein; John E Warner; Kathleen G Lambert; Sarah E Cole; Andrew B Onderdonk; Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 10.  Addressing the burden of group A streptococcal disease in India.

Authors:  Anita Shet; Edward Kaplan
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.